Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type A

References

• JankovicJDisease-oriented approach to botulinum toxin useToxicon200954561462319073203
   PubMed Web of Science ®Google Scholar
• TruongDBotulinum toxins in the treatment of primary focal dystoniasJ Neurol Sci20123161–291422336699
   PubMed Web of Science ®Google Scholar
• AlbaneseABhatiaKBressmanSBPhenomenology and classification of dystonia: a consensus updateMov Disord201328786387323649720
   PubMed Web of Science ®Google Scholar
• JankovicJTsuiJBergeronCPrevalence of cervical dystonia and spasmodic torticollis in the United States general populationParkinsonism Relat Disord200713741141617442609
   PubMed Web of Science ®Google Scholar
• NuttJGMuenterMDAronsonAKurlandLTMeltonLJ3rdEpidemiology of focal and generalized dystonia in Rochester, MinnesotaMov Disord1988331881943264051
   PubMed Web of Science ®Google Scholar
• KesslerKRSkuttaMBeneckeRLong-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study GroupJ Neurol1999246426527410367694
   PubMed Web of Science ®Google Scholar
• JankovicJLederSWarnerDSchwartzKCervical dystonia: clinical findings and associated movement disordersNeurology1991417108810912067638
   PubMed Web of Science ®Google Scholar
• CostaJEspirito-SantoCBorgesAFerreiraJJCoelhoMSampaioCBotulinum toxin type A versus anticholinergics for cervical dystonia [review]Cochrane Database Syst Rev20051CD00431215674939
   PubMedGoogle Scholar
• HallettMBeneckeRBlitzerAComellaCLTreatment of focal dystonias with botulinum neurotoxinToxicon200954562863319103214
   PubMed Web of Science ®Google Scholar
• ChanJBrinMFFahnSIdiopathic cervical dystonia: clinical characteristicsMov Disord1991621191262057004
   PubMed Web of Science ®Google Scholar
• NijmeijerSWKoelmanJHKamphuisDJTijssenMAMuscle selection for treatment of cervical dystonia with botulinum toxin – a systematic reviewParkinsonism Relat Disord201218673173622575237
   PubMed Web of Science ®Google Scholar
• ErroRBhatiaKPCataniaSShieldsKCordivariCWhen the levator scapulae becomes a “rotator capitis”: implications for cervical dystoniaParkinsonism Relat Disord201319770570623611686
   PubMed Web of Science ®Google Scholar
• PatelNHanfeltJMarshLJankovicJMembers of the Dystonia CoalitionAlleviating manoeuvres (sensory tricks) in cervical dystoniaJ Neurol Neurosurg Psychiatry201485888288424828895
   PubMed Web of Science ®Google Scholar
• TideringtonEGoodmanEMRosenARHow long does it take to diagnose cervical dystonia?J Neurol Sci20133351–2727424034410
   PubMed Web of Science ®Google Scholar
• Van GerpenJAMatsumotoJYAhlskogJEMaraganoreDMMcManisPGUtility of an EMG mapping study in treating cervical dystoniaMuscle Nerve200023111752175611054755
   PubMed Web of Science ®Google Scholar
• MüllerJKemmlerGWisselJAustrian Botulinum Toxin and Dystonia Study GroupThe impact of blepharospasm and cervical dystonia on health-related quality of life and depressionJ Neurol2002249784284612140667
   PubMed Web of Science ®Google Scholar
• GündelHWolfAXidaraVBuschRCeballos-BaumannAOSocial phobia in spasmodic torticollisJ Neurol Neurosurg Psychiatry200171449950411561034
   PubMed Web of Science ®Google Scholar
• ColosimoCTipleDBerardelliAEfficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic reviewNeurotox Res201222426527322359151
   PubMed Web of Science ®Google Scholar
• Ramirez-CastanedaJJankovicJLong-term efficacy and safety of botulinum toxin injections in dystoniaToxins (Basel)20135224926623381141
   PubMed Web of Science ®Google Scholar
• TagliatiMKrackPVolkmannJLong-term management of DBS in dystonia: response to stimulation, adverse events, battery changes, and special considerationsMov Disord201126Suppl 1S54S6221692113
   PubMed Web of Science ®Google Scholar
• FordBLouisEDGreenePFahnSOutcome of selective ramisectomy for botulinum toxin resistant torticollisJ Neurol Neurosurg Psychiatry19986544724789771768
   PubMed Web of Science ®Google Scholar
• MünchauAPalmerJDDresslerDProspective study of selective peripheral denervation for botulinumtoxin resistant patients with cervical dystoniaBrain2001124Pt 476978311287376
   PubMed Web of Science ®Google Scholar
• BraunVRichterHPSelective peripheral denervation for spasmodic torticollis: 13-year experience with 155 patientsJ Neurosurg2002972 Suppl20721212296680
   PubMed Web of Science ®Google Scholar
• De PauwJVan der VeldenKMeirteJThe effectiveness of physiotherapy for cervical dystonia: a systematic literature reviewJ Neurol2014261101857186524413637
   PubMed Web of Science ®Google Scholar
• QueirozMAChienHFSekeff-SallemFABarbosaERPhysical therapy program for cervical dystonia: a study of 20 casesFunct Neurol201227318719223402680
   PubMed Web of Science ®Google Scholar
• AlbaneseASorboFDComellaCDystonia rating scales: critique and recommendationsMov Disord201328787488323893443
   PubMed Web of Science ®Google Scholar
• LacyBEWeiserKKennedyABotulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future?Gastroenterol Hepatol (N Y)20084428329521960915
   PubMedGoogle Scholar
• ErbguthFJHistorical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxinMov Disord200419Suppl 8S2S615027048
   PubMed Web of Science ®Google Scholar
• CharlesDGillCENeurotoxin injection for movement disordersContinuum (Minneap Minn)2010161 Movement Disorders13115722810184
   PubMedGoogle Scholar
• HallettMAlbaneseADresslerDEvidence-based review and assessment of botulinum neurotoxin for the treatment of movement disordersToxicon2013679411423380701
   PubMed Web of Science ®Google Scholar
• SimpsonDMBlitzerABrashearATherapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyAssessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyNeurology200870191699170618458230
   PubMed Web of Science ®Google Scholar
• TsuiJKEisenAStoesslAJCalneSCalneDBDouble-blind study of botulinum toxin in spasmodic torticollisLancet1986285012452472874278
   PubMed Web of Science ®Google Scholar
• GreenePKangUFahnSBrinMMoskowitzCFlasterEDouble-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollisNeurology1990408121312182199847
   PubMed Web of Science ®Google Scholar
• BrinMFFahnSMoskowitzCLocalized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasmAdv Neurol1988505996083400513
   PubMedGoogle Scholar
• GelbDJLowensteinDHAminoffMJControlled trial of botulinum toxin injections in the treatment of spasmodic torticollisNeurology198939180842642616
   PubMed Web of Science ®Google Scholar
• JankovicJBotulinum toxin therapy for cervical dystoniaNeurotox Res200692–314514816785112
   PubMed Web of Science ®Google Scholar
• NaumannMJankovicJSafety of botulinum toxin type A: a systematic review and meta-analysisCurr Med Res Opin200420798199015265242
   PubMed Web of Science ®Google Scholar
• ChapmanMABarronRTanisDCGillCECharlesPDComparison of botulinum neurotoxin preparations for the treatment of cervical dystoniaClin Ther20072971325133717825685
   PubMed Web of Science ®Google Scholar
• TruongDBrodskyMLewMGlobal Dysport Cervical Dystonia Study GroupLong-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystoniaParkinsonism Relat Disord201016531632320359934
   PubMed Web of Science ®Google Scholar
• PoeweWDeuschlGNebeAWhat is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study GroupJ Neurol Neurosurg Psychiatry199864113179436721
   PubMed Web of Science ®Google Scholar
• TruongDDuaneDDJankovicJEfficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled studyMov Disord200520778379115736159
   PubMed Web of Science ®Google Scholar
• WisselJKanovskyPRuzickaEEfficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group studyJ Neurol2001248121073107812013585
   PubMed Web of Science ®Google Scholar
• BeneckeRJostWHKanovskyPRuzickaEComesGGrafeSA new botulinum toxin type A free of complexing proteins for treatment of cervical dystoniaNeurology200564111949195115955951
   PubMed Web of Science ®Google Scholar
• ComellaCLJankovicJTruongDDHanschmannAGrafe S;US. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystoniaJ Neurol Sci20113081–210310921764407
   PubMed Web of Science ®Google Scholar
• ComellaCLJankovicJShannonKMDystonia Study GroupComparison of botulinum toxin serotypes A and B for the treatment of cervical dystoniaNeurology20056591423142916275831
   PubMed Web of Science ®Google Scholar
• Baizabal-CarvalloJFJankovicJPappertEFlu-like symptoms following botulinum toxin therapyToxicon20115811721620881
   PubMed Web of Science ®Google Scholar
• MarshWAMonroeDMBrinMFGallagherCJSystematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystoniaBMC Neurol2014149124767576
   PubMed Web of Science ®Google Scholar
• ZoonsEDijkgraafMGWDijkJMvan SchaikINTijssenMABotulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic valueJ Neurol2012259122519252622552527
   PubMed Web of Science ®Google Scholar